News
Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?
Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect…
Current Findings on Progressive Fibrosis in Interstitial Lung Disease
Leading pulmonologists around the world recently published the first of a series of three review…
Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence
Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The…
Current Treatment Options for Refractory/Relapsed CLL
How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review…
New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference…
Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps
The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab,…
Current Challenges in Diagnosing Progressive Fibrotic Interstitial Lung Diseases
A subset of patients with interstitial lung diseases exhibits a progressive fibrotic phenotype…
Limosilactobacillus reuteri as a supplement for improving periodontal health when oral hygiene is compromised
The effect of probiotics on periodontal health was investigated in a German study conducted on a…
Probiotics as a Helper in the Fight Against Pregnancy Gingivitis
Gingivitis is a common problem during pregnancy. In addition to quality oral hygiene, regular…